SCHEMBL4619410

SCHEMBL4619410

Cc1ccc(S(=O)(=O)c2ccccc2)cc1S(=O)(=O)NC1CC1

nearest known ligand 0.57

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SFRP1 Q8N474 12/20 0.57
WNT3 P56703 4/20 0.57
BRD4 O60885 3/20 0.53
BRD2 P25440 2/20 0.53
BRD3 Q15059 2/20 0.53
ALDH1A1 P00352 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4619287 0.95 ALDH1A1 (0.58) SFRP1WNT3BRD4BRD2BRD3
SCHEMBL4618174 0.95 SFRP1 (0.55) SFRP1WNT3BRD4BRD2BRD3
SCHEMBL4615963 0.93 ALDH1A1 (0.57) SFRP1WNT3BRD4BRD2BRD3
SCHEMBL4617045 0.91 SFRP1 (0.52) SFRP1WNT3BRD4BRD2BRD3
SCHEMBL6103185 0.91 ALDH1A1 (0.58) SFRP1WNT3BRD4BRD2BRD3
SCHEMBL4616681 0.91 SFRP1 (0.70) SFRP1WNT3BRD4BRD2BRD3
SCHEMBL4638257 0.88 SFRP1 (0.54) SFRP1WNT3BRD4BRD2BRD3
SCHEMBL4616152 0.88 SFRP1 (0.60) SFRP1WNT3ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4618344 0.88 SFRP1 (0.72) SFRP1WNT3ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4618255 0.86 SFRP1 (0.59) SFRP1WNT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101208299-A Diarylsulfone sulfonamides and use therof WYETH CORP (US) 2008-06-25 CN claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
CN-101208299-A Diarylsulfone sulfonamides and use therof WYETH CORP (US) 2008-06-25 CN disclosed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 SFRP1 1/4885WNT3 346/4885BRD4 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.